MINNEAPOLIS, Jan. 30, 2024 /PRNewswire/ — Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to initiate a clinical study of the ReCET System for the treatment of T2D in adult patients, inadequately controlled by non-insulin, glucose lowering medications.
Bringing new energy to the treatment of Type 2 Diabetes (PRNewsfoto/Endogenex)
The ReCET Clinical Study is a multicenter, prospective, randomized, double blinded, sham controlled study assessing the safety and effectiveness of the ReCET™ System. The pivotal study will enroll up to 350 patients at clinical sites in the United States and Australia.
“Endogenex is excited to achieve this important clinical milestone,” said Stacey Pugh, Endogenex CEO. “This is a critical next step in advancing the ReCET Procedure as a treatment that addresses the underlying causes of T2D that are not targeted by current diabetes medications.”
“Many people living with T2D struggle to remain in control of their blood sugar levels, even while using modern glucose lowering medications. This presents a significant challenge for patients and their care providers,” stated Richard Pratley, MD, Medical Director of the Advent Health Diabetes Institute in Orlando, Florida and Co-Principal Investigator for the ReCET Study. “Preliminary results of the ReCET Procedure have been very encouraging, so we look forward to participating in this study and expanding the understanding of how it may fulfill a significant need in the care of this patient population.”